Cargando…
RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer
SIMPLE SUMMARY: Breast cancer is the second leading cause of death in women. Identifying novel genetic factors conferring BC predisposition is crucial to predict who is at increased risk of developing the disease, allowing for early detection and therapy, and optimized patient management. We identif...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563829/ https://www.ncbi.nlm.nih.gov/pubmed/32906649 http://dx.doi.org/10.3390/cancers12092539 |
_version_ | 1783595575553294336 |
---|---|
author | Isidori, Federica Bozzarelli, Isotta Ferrari, Simona Godino, Lea Innella, Giovanni Turchetti, Daniela Bonora, Elena |
author_facet | Isidori, Federica Bozzarelli, Isotta Ferrari, Simona Godino, Lea Innella, Giovanni Turchetti, Daniela Bonora, Elena |
author_sort | Isidori, Federica |
collection | PubMed |
description | SIMPLE SUMMARY: Breast cancer is the second leading cause of death in women. Identifying novel genetic factors conferring BC predisposition is crucial to predict who is at increased risk of developing the disease, allowing for early detection and therapy, and optimized patient management. We identified germline pathogenic variants in familial breast cancer patients in ROS1 and RASAL1 genes. Further analysis in independent patient group will help understanding the role of these novel genes in breast cancer predisposition. ABSTRACT: Breast cancer (BC) is the second leading cause of death in women. BC patients with family history or clinical features suggestive of inherited predisposition are candidate to genetic testing to determine whether a hereditary cancer syndrome is present. We aimed to identify new predisposing variants in familial BC patients using next-generation sequencing approaches. We performed whole exome sequencing (WES) in first-degree cousin pairs affected by hereditary BC negative at the BRCA1/2 (BReast CAncer gene 1/2) testing. Targeted analysis, for the genes resulting mutated via WES, was performed in additional 131 independent patients with a suspected hereditary predisposition (negative at the BRCA1/2 testing). We retrieved sequencing data for the mutated genes from WES of 197 Italian unrelated controls to perform a case-controls collapsing analysis. We found damaging variants in NPL (N-Acetylneuraminate Pyruvate Lyase), POLN (DNA Polymerase Nu), RASAL1 (RAS Protein Activator Like 1) and ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), shared by the corresponding cousin pairs. We demonstrated that the splice site alterations identified in NPL and ROS1 (in two different pairs, respectively) impaired the formation of the correct transcripts. Target analysis in additional patients identified novel and rare damaging variants in RASAL1 and ROS1, with a significant allele frequency increase in cases. Moreover, ROS1 achieved a significantly higher proportion of variants among cases in comparison to our internal control database of Italian subjects (p = 0.0401). Our findings indicate that germline variants in ROS1 and RASAL1 might confer susceptibility to BC. |
format | Online Article Text |
id | pubmed-7563829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75638292020-10-27 RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer Isidori, Federica Bozzarelli, Isotta Ferrari, Simona Godino, Lea Innella, Giovanni Turchetti, Daniela Bonora, Elena Cancers (Basel) Article SIMPLE SUMMARY: Breast cancer is the second leading cause of death in women. Identifying novel genetic factors conferring BC predisposition is crucial to predict who is at increased risk of developing the disease, allowing for early detection and therapy, and optimized patient management. We identified germline pathogenic variants in familial breast cancer patients in ROS1 and RASAL1 genes. Further analysis in independent patient group will help understanding the role of these novel genes in breast cancer predisposition. ABSTRACT: Breast cancer (BC) is the second leading cause of death in women. BC patients with family history or clinical features suggestive of inherited predisposition are candidate to genetic testing to determine whether a hereditary cancer syndrome is present. We aimed to identify new predisposing variants in familial BC patients using next-generation sequencing approaches. We performed whole exome sequencing (WES) in first-degree cousin pairs affected by hereditary BC negative at the BRCA1/2 (BReast CAncer gene 1/2) testing. Targeted analysis, for the genes resulting mutated via WES, was performed in additional 131 independent patients with a suspected hereditary predisposition (negative at the BRCA1/2 testing). We retrieved sequencing data for the mutated genes from WES of 197 Italian unrelated controls to perform a case-controls collapsing analysis. We found damaging variants in NPL (N-Acetylneuraminate Pyruvate Lyase), POLN (DNA Polymerase Nu), RASAL1 (RAS Protein Activator Like 1) and ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), shared by the corresponding cousin pairs. We demonstrated that the splice site alterations identified in NPL and ROS1 (in two different pairs, respectively) impaired the formation of the correct transcripts. Target analysis in additional patients identified novel and rare damaging variants in RASAL1 and ROS1, with a significant allele frequency increase in cases. Moreover, ROS1 achieved a significantly higher proportion of variants among cases in comparison to our internal control database of Italian subjects (p = 0.0401). Our findings indicate that germline variants in ROS1 and RASAL1 might confer susceptibility to BC. MDPI 2020-09-07 /pmc/articles/PMC7563829/ /pubmed/32906649 http://dx.doi.org/10.3390/cancers12092539 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Isidori, Federica Bozzarelli, Isotta Ferrari, Simona Godino, Lea Innella, Giovanni Turchetti, Daniela Bonora, Elena RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title | RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title_full | RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title_fullStr | RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title_full_unstemmed | RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title_short | RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer |
title_sort | rasal1 and ros1 gene variants in hereditary breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563829/ https://www.ncbi.nlm.nih.gov/pubmed/32906649 http://dx.doi.org/10.3390/cancers12092539 |
work_keys_str_mv | AT isidorifederica rasal1andros1genevariantsinhereditarybreastcancer AT bozzarelliisotta rasal1andros1genevariantsinhereditarybreastcancer AT ferrarisimona rasal1andros1genevariantsinhereditarybreastcancer AT godinolea rasal1andros1genevariantsinhereditarybreastcancer AT innellagiovanni rasal1andros1genevariantsinhereditarybreastcancer AT turchettidaniela rasal1andros1genevariantsinhereditarybreastcancer AT bonoraelena rasal1andros1genevariantsinhereditarybreastcancer |